Render Target: SSR
Render Timestamp: 2024-11-14T22:58:26.920Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-08-01 15:25:20.805
Product last modified at: 2024-09-26T12:15:14.159Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

Phospho-HDAC4 (Ser632)/HDAC5 (Ser661)/HDAC7 (Ser486) Antibody #3424

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 140, 124, 120
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:25

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Phospho-HDAC4 (Ser632)/HDAC5 (Ser661)/HDAC7 (Ser486) Antibody recognizes endogenous levels of HDAC4, HDAC5 and HDAC7 proteins when phosphorylated on Ser632, Ser661 and Ser486, respectively. The antibody may recognize HDAC4 phosphorylated at Ser467 and HDAC5 phosphorylated at Ser498. The antibody also crossreacts with an unidentified protein at 80 kDa.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to human HDAC7 protein phosphorylated on Ser486. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    Acetylation of the histone tail causes chromatin to adopt an "open" conformation, allowing increased accessibility of transcription factors to DNA. The identification of histone acetyltransferases (HATs) and their large multiprotein complexes has yielded important insights into how these enzymes regulate transcription (1,2). HAT complexes interact with sequence-specific activator proteins to target specific genes. In addition to histones, HATs can acetylate nonhistone proteins, suggesting multiple roles for these enzymes (3). In contrast, histone deacetylation promotes a "closed" chromatin conformation and typically leads to repression of gene activity (4). Mammalian histone deacetylases can be divided into three classes on the basis of their similarity to various yeast deacetylases (5). Class I proteins (HDACs 1, 2, 3, and 8) are related to the yeast Rpd3-like proteins, those in class II (HDACs 4, 5, 6, 7, 9, and 10) are related to yeast Hda1-like proteins, and class III proteins are related to the yeast protein Sir2. Inhibitors of HDAC activity are now being explored as potential therapeutic cancer agents (6,7).
    Histone deacetylases (HDACs) interact with an increasing number of transcription factors, including myocyte enhancer factor 2 (MEF2), to negatively regulate gene expression. HDACs are regulated in part by shuttling between the nucleus and cytoplasm, where export to the cytoplasm facilitates gene activation by removing HDACs from their target genes (8,9). The cytoplasmic export is facilitated by 14-3-3 proteins, which bind to specific phospho-serine residues on the HDAC proteins (8,9). These phospho-serine 14-3-3 binding modules are highly conserved between HDAC proteins, allowing for their collective regulation in response to specific cell stimuli. For example, the highly conserved HDAC 4 Ser632, HDAC 5 Ser498 and HDAC 7 Ser486 residues are all phosphorylated by CAMK and PKD kinases in response to multiple cell stimuli, including VEGF-induced angiogenesis in endothelial cells, B cell and T cell activation, and differentiation of myoblasts into muscle fiber (10-14).
    1. Marmorstein, R. (2001) Cell Mol Life Sci 58, 693-703.
    2. Gregory, P.D. et al. (2001) Exp Cell Res 265, 195-202.
    3. Liu, Y. et al. (2000) Mol Cell Biol 20, 5540-53.
    4. Cress, W.D. and Seto, E. (2000) J Cell Physiol 184, 1-16.
    5. Gray, S.G. and Ekström, T.J. (2001) Exp Cell Res 262, 75-83.
    6. Thiagalingam, S. et al. (2003) Ann. N.Y. Acad. Sci. 983, 84-100.
    7. Vigushin, D.M. and Coombes, R.C. (2004) Curr Cancer Drug Targets 4, 205-18.
    8. Grozinger, C.M. and Schreiber, S.L. (2000) Proc Natl Acad Sci USA 97, 7835-40.
    9. Wang, A.H. et al. (2000) Mol Cell Biol 20, 6904-12.
    10. Ha, C.H. et al. (2008) J Biol Chem 283, 14590-9.
    11. Wang, S. et al. (2008) Proc Natl Acad Sci U S A 105, 7738-43.
    12. Matthews, S.A. et al. (2006) Mol Cell Biol 26, 1569-77.
    13. Parra, M. et al. (2005) J Biol Chem 280, 13762-70.
    14. McKinsey, T.A. et al. (2000) Nature 408, 106-11.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.